Completed PHASE3 INTERVENTIONAL 5-arm NCT03597867

PGE2 Levels in Patient Treated With NSAIDs

Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients

Sponsor: University of Trieste

Conditions Ocular Inflammation

Interventions Dicloftil Indom Nevanac Placebo Yellox

Updated 4 times since 2018 Last updated: Jul 21, 2018 Started: Apr 25, 2018 Primary completion: Jul 5, 2018 Completion: Jul 9, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ocular Inflammation and is currently completed. University of Trieste leads this study, which shows 4 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Trieste

Data source: University of Trieste

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Trieste, Italy